Search research articles
Contact Us
Filters
Showing results (21-30 of 31) with videos related to
Page
of 4
Sort By:
ACS Chemical Neuroscience
|
January 7, 2015
Molecular determinants of α-synuclein mutants' oligomerization and membrane interactions
Igor F Tsigelny, Yuriy Sharikov, Valentina L Kouznetsova, et al.
Frontiers in Neuroscience
|
July 14, 2023
Modeling Alzheimer's disease related phenotypes in the Ts65Dn mouse: impact of age on Aβ, Tau, pTau, NfL, and behavior
Cassia Overk, Emma Fiorini, Chiara Babolin, et al.
Neurobiology of Disease
|
January 16, 2025
Retraction Notice to "Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy" [Neurobiology of Disease 104 (2017) 85-96]
Omar El-Agnaf, Cassia Overk, Edward Rockenstein, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
November 10, 2021
Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model
Mariko Sawa, Cassia Overk, Ann Becker, et al.
Neurobiology of Disease
|
May 7, 2017
Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy
Omar El-Agnaf, Cassia Overk, Edward Rockenstein, et al.
Acta Neuropathologica Communications
|
March 27, 2026
Retraction Note: Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy
Brian Spencer, Elvira Valera, Edward Rockenstein, et al.
Acta Neuropathologica Communications
|
January 15, 2017
Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy
Brian Spencer, Elvira Valera, Edward Rockenstein, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
August 6, 2019
Effects of single and combined immunotherapy approach targeting amyloid β protein and α-synuclein in a dementia with Lewy bodies-like model
Markus Mandler, Edward Rockenstein, Cassia Overk, et al.
Science Translational Medicine
|
May 10, 2023
Inhibition of p38α MAPK restores neuronal p38γ MAPK and ameliorates synaptic degeneration in a mouse model of DLB/PD
Michiyo Iba, Changyoun Kim, Somin Kwon, et al.
Frontiers in Neuroscience
|
September 18, 2023
Nicotine-mediated effects in neuronal and mouse models of synucleinopathy
Mohamed Bilal Fares, Omar Alijevic, Stephanie Johne, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 31) with videos related to
Sort By:
Page
of 4
ACS Chemical Neuroscience
|
January 7, 2015
Molecular determinants of α-synuclein mutants' oligomerization and membrane interactions
Igor F Tsigelny, Yuriy Sharikov, Valentina L Kouznetsova, et al.
Frontiers in Neuroscience
|
July 14, 2023
Modeling Alzheimer's disease related phenotypes in the Ts65Dn mouse: impact of age on Aβ, Tau, pTau, NfL, and behavior
Cassia Overk, Emma Fiorini, Chiara Babolin, et al.
Neurobiology of Disease
|
January 16, 2025
Retraction Notice to "Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy" [Neurobiology of Disease 104 (2017) 85-96]
Omar El-Agnaf, Cassia Overk, Edward Rockenstein, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
November 10, 2021
Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model
Mariko Sawa, Cassia Overk, Ann Becker, et al.
Neurobiology of Disease
|
May 7, 2017
Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy
Omar El-Agnaf, Cassia Overk, Edward Rockenstein, et al.
Acta Neuropathologica Communications
|
March 27, 2026
Retraction Note: Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy
Brian Spencer, Elvira Valera, Edward Rockenstein, et al.
Acta Neuropathologica Communications
|
January 15, 2017
Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy
Brian Spencer, Elvira Valera, Edward Rockenstein, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
August 6, 2019
Effects of single and combined immunotherapy approach targeting amyloid β protein and α-synuclein in a dementia with Lewy bodies-like model
Markus Mandler, Edward Rockenstein, Cassia Overk, et al.
Science Translational Medicine
|
May 10, 2023
Inhibition of p38α MAPK restores neuronal p38γ MAPK and ameliorates synaptic degeneration in a mouse model of DLB/PD
Michiyo Iba, Changyoun Kim, Somin Kwon, et al.
Frontiers in Neuroscience
|
September 18, 2023
Nicotine-mediated effects in neuronal and mouse models of synucleinopathy
Mohamed Bilal Fares, Omar Alijevic, Stephanie Johne, et al.
Page
of 4